Hardman & Co Research
Hardman & Co Research: Oxford BioMedica (OXB): Demanding second half
16-Oct-2019 / 07:30 GMT/BST
Hardman & Co Research: Demanding second half
Oxford BioMedica (OXB) is a gene-based medicine viral-vector biopharma
company. It offers vector manufacturing and development services, while
developing proprietary therapies, with its LentiVector(R) platform. Growth in
gross income and profitability were driven by new licensing deals in 2018.
Despite steady growth in 1H'19 group sales (bioprocessing and commercial
development), a reduction in licensing income resulted in a first-half
operating loss; the absence of significant deals in 2019 has also dampened the
shares. Although interim results were in line with our expectations, they
highlight the importance of 2H'19 for a full-year profit.
Please click on the link below for the full report:
https://www.hardmanandco.com/research/corporate-research/demanding-second-half
/ [1]
If you are interested in meeting the company, you can register your interest
by clicking on the above link
To contact us: Contact:
Hardman & Co Dr Martin Hall mh@hardmanandco.com
35 New Broad Street dmh@hardmanandco.com
London gp@hardmanandco.com
EC2M 1NH
Dr Dorothea
Hill
www.hardmanandco.com
Dr Gregoire
Pave
Follow us on Twitter
@HardmanandCo +44 20 7194
7622
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing
specialist research designed to improve investors' understanding of companies,
sectors, industries and investment securities. Our analysts are highly
experienced in their sectors, and have often been highly rated by professional
investors for their knowledge. Our focus is to raise companies' profiles
across the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been commissioned by
the company which is the subject of the note; this is clearly stated in the
disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative
of Capital Markets Strategy Ltd and is authorised and regulated by the
Financial Conduct Authority; our FCA registration number is 600843. Hardman
Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community,
market counterparties and sophisticated and high net worth investors as
defined in the rules of the regulatory bodies. It is not intended to be made
available to unsophisticated retail investors. Anyone who is unsure of their
categorisation should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security. Please read
the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
890525 16-Oct-2019
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=54ae825af45224af3053187794070131&application_id=890525&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=890525&site_id=vwd&application_name=news
(END) Dow Jones Newswires
October 16, 2019 02:30 ET (06:30 GMT)
